Showing results (1-10 of 36) with videos related to

Sort By:
Pageof 4
Therapeutic Advances in Drug Safety|October 9, 2024
Disproportionality analysis of reslizumab based on the FDA Adverse Event Reporting SystemHuqun Li, Cuilian Guo, Chongshu Wang
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|November 20, 2020
Metformin ameliorates olanzapine-induced insulin resistance via suppressing macrophage infiltration and inflammatory responses in ratsCuilian Guo, Jinxin Liu, Huqun Li
Frontiers in Pharmacology|June 21, 2024
Post-marketing safety of lorlatinib: a real-world study based on the FDA adverse event reporting systemHuqun Li, Chongshu Wang, Cuilian Guo
The Journal of Allergy and Clinical Immunology. in Practice|November 9, 2024
A Pharmacovigilance Analysis of Post-Marketing Safety of TezepelumabHuqun Li, Chongshu Wang, Cuilian Guo
Lupus Science & Medicine|January 10, 2025
Postmarketing safety evaluation of belimumab: a pharmacovigilance analysisHuqun Li, Wenlong Xie, Chongshu Wang, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|August 27, 2021
JNK downregulation improves olanzapine-induced insulin resistance by suppressing IRS1Ser307 phosphorylation and reducing inflammationHuqun Li, Chongshu Wang, Jiefang Zhao, et al.
Frontiers in Pharmacology|December 25, 2023
A real-world disproportionality analysis of mepolizumab based on the FDA adverse event reporting systemHuqun Li, Chongshu Wang, Aiping Deng, et al.
Pageof 4